Lurbinectedin is a chemotherapy drug used to treat small cell lung cancer (SCLC). According to the sources provided, there is no clear information regarding whether lurbinectedin can be used with all immunotherapies.

One article from OncLive [2] explains that lurbinectedin has been shown to be effective in combination with immunotherapy drugs such as pembrolizumab in treating relapsed SCLC. However, the article does not provide information about whether lurbinectedin can be used with all immunotherapies.

Another article from Cancer Network [3] highlights the promising preliminary activity of lurbinectedin and pembrolizumab in relapsed SCLC. However, the article does not mention whether lurbinectedin can be used with all immunotherapies.

A third source, Drug Patent Watch [1], provides information on the patent for lurbinectedin, but does not provide any information on its use with immunotherapies.

Therefore, based on the sources provided, there is no clear information on whether lurbinectedin can be used with all immunotherapies. Further research is needed to determine the compatibility of lurbinectedin with various immunotherapy drugs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.onclive.com/view/navigating-newfound-options-in-sclc-with-immunotherapy-and-lurbinectedin
[3] https://www.cancernetwork.com/view/antonio-calles-md-highlights-promising-preliminary-activity-of-lurbinectedin-and-pembrolizumab-in-relapsed-sclc